

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/185418/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Ougrin, Dennis, Thaventhiran, Thilipan, Wong, Ben Hoi-Ching, Pilecka, Izabela, Landau, Sabine, Byford, Sarah, Chu, Petrina, Jafari, Hassan, Heslin, Margaret, Tassie, Emma, Reavey, Paula, Zundel, Toby, Wait, Mandy, Woolhouse, Ruth, Mehdi, Tauseef, Tolmac, Jovanka, Clacey, Joe, Wehncke, Leon, Dobler, Veronika Beatrice and Bevan-Jones, Rhys 2026. Intensive community care services for adolescents with acute psychiatric emergencies: trial feasibility findings from the pilot phase of a multi-centre randomised controlled trial. *BMC Psychiatry* 10.1186/s12888-025-07528-2

Publishers page: <https://doi.org/10.1186/s12888-025-07528-2>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Intensive community care services for adolescents with acute psychiatric emergencies: trial feasibility findings from the pilot phase of a multi-centre randomised controlled trial

Received: 5 March 2025

Accepted: 13 October 2025

Published online: 19 February 2026

Cite this article as: Ougrin D., Thaventhiran T., Wong B.H. *et al.*

Intensive community care services for adolescents with acute psychiatric emergencies: trial feasibility findings from the pilot phase of a multi-centre randomised controlled trial. *BMC Psychiatry* (2025). <https://doi.org/10.1186/s12888-025-07528-2>

Dennis Ougrin, Thilipan Thaventhiran, Ben Hoi-Ching Wong, Izabela Pilecka, Sabine Landau, Sarah Byford, Petrina Chu, Hassan Jafari, Margaret Heslin, Emma Tassie, Paula Reavey, Toby Zundel, Mandy Wait, Ruth Woolhouse, Tauseef Mehdi, Jovanka Tolmac, Joe Clacey, Leon Wehncke, Veronika Beatrice Dobler & Rhys Bevan-Jones

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

If this paper is publishing under a Transparent Peer Review model then Peer Review reports will publish with the final article.

1 Intensive Community Care Services for Adolescents with Acute 2 Psychiatric Emergencies: Trial Feasibility Findings from the Pilot 3 Phase of a Multi-centre Randomised Controlled Trial

4 Dennis Ougrin¹, Thilipan Thaventhiran¹, Ben Hoi-Ching Wong², Izabela Pilecka³, Sabine Landau³, Sarah
5 Byford³, Petrina Chu³, Hassan Jafari³, Margaret Heslin³, Emma Tassie³, Paula Reavey⁴, Toby Zundel⁵,
6 Mandy Wait⁵, Ruth Woolhouse², Tauseef Mehdi⁶, Jovanka Tolmac⁷, Joe Clacey⁸, Leon Wehncke⁹,
7 Veronika Beatrice Dobler¹⁰, Rhys Bevan-Jones¹¹

8 Abstract

9 Background:

10 Adolescents experiencing psychiatric emergencies often require intensive intervention to avoid
11 hospital admission and support their transition into education, employment, or training (EET).
12 Intensive Community Care Services (ICCS) offer a potential alternative to inpatient care. This pilot
13 study aimed to assess the feasibility of conducting a randomised controlled trial (RCT) to evaluate
14 the effectiveness of ICCS compared to treatment as usual (TAU) in reducing time to start or return
15 to EET.

16

17 Methods:

18 A multi-centre, parallel-group, single-blinded randomised controlled trial (RCT) with an internal
19 pilot phase was conducted across seven NHS Trusts in the UK. Adolescents aged 12–17
20 experiencing psychiatric emergencies were randomised to ICCS or treatment as usual (TAU).
21 The primary outcome was time to start or return to EET within six months. Secondary outcomes
22 included clinical symptoms, functioning, service satisfaction, service use, and health-related
23 quality of life. Descriptive statistics and hazard ratios were calculated to explore group differences.
24 Feasibility was assessed against pre-specified progression criteria.

25

26 Results:

27 Thirty-six adolescents were randomised during the internal pilot phase. The recruitment rate did
28 not meet the progression criteria, and continuation to a full evaluation trial was deemed
29 unfeasible. During follow-up, 83.3% (n=30) returned to EET, with a median time to EET of nine
30 days (IQR: 1–49). Median time to EET was shorter in the ICCS group (6 days) compared to TAU
31 (12 days), with a hazard ratio of 1.34 (95% CI: 0.63–2.86). ICCS was associated with improved
32 service satisfaction, clinical symptoms, and functioning. The average cost per participant was
33 higher in the TAU group (£15,155, SD 31,560) compared to ICCS (£7,063, SD 10,605), with
34 minimal differences in quality-adjusted life years (QALYs). Fourteen safety events were reported
35 across both groups.

36

37 Conclusions:

38 A full evaluation trial was not feasible due to recruitment challenges, primarily arising from limited-
39 service capacity to deliver two treatment pathways concurrently. Despite this, ICCS showed
40 promising trends in clinical and functional outcomes and may offer a viable alternative to inpatient

41 care. Further research is needed to explore the implementation and effectiveness of ICCS in
42 routine practice.

43

44 **Trial registration:**

45 ISRCTN, ISRCTN42999542. Registered 29/04/2020, <https://doi.org/10.1186/ISRCTN42999542>

46 **Keywords:**

47 Adolescent psychiatry, Intensive Community Care, psychiatric emergencies, employment,
48 education, feasibility assessment, randomised controlled trial

49

50 **Background**

51

52 Mental health crises among children and young people (CYP) are a significant public health
53 concern. A recent National Health Service (NHS) survey in England revealed that approximately
54 1 in 6 children aged 5–16 years are likely to have a mental health disorder (1). In 2021-2022, over
55 1.2 million CYP were referred for mental health support, marking a 41% increase from the
56 previous year (2). While Tier 4 Child and Adolescent Mental Health Services (CAMHS) inpatient
57 units play a critical role in stabilising severe psychiatric conditions, they often result in prolonged
58 admissions, with an average hospital stay of 120 days across all psychiatric units (3). Repeated
59 and lengthy admissions can lead to interpersonal disconnection and increased strain on the
60 healthcare system, exacerbating the challenges of providing timely, effective mental health care
61 for young people (4).

62

63 Intensive Community Care Services (ICCS) for children and adolescents with severe psychiatric
64 disorders, including home treatment, crisis teams, day services, and other intensive treatment
65 teams, have been prioritised by national policy and commissioners in many countries (5).
66 According to the NHS Long Term Plan, all NHS trusts must provide a form of ICCS in England by
67 the end of 2024 (6). Despite this mandate, there is minimal evidence for the efficacy or
68 effectiveness of ICCS (7). Recent systematic reviews indicate that studies of ICCS are highly
69 heterogeneous, with varying outcome measures and inconsistent comparisons (8). Most studies
70 have compared ICCS with inpatient care rather than other community-based services, limiting the
71 understanding of its true effectiveness in real-world settings (9). Given these gaps in the evidence
72 base, there is an urgent need for robust research on the clinical and cost-effectiveness of ICCS.
73 The Comparison of Effectiveness and Cost-effectiveness of Intensive Community Care Services
74 versus Treatment as Usual Including Inpatient Care for Young People with Psychiatric
75 Emergencies (IVY) trial aimed to evaluate the impact of ICCS on time to return to or start
76 education, employment, or training (EET), a key indicator of long-term recovery for CYP (10), as
77 well as on a range of secondary outcomes, including psychopathology, functioning, and service
78 satisfaction (11). The study design included an internal pilot phase to assess the feasibility of
79 conducting a full evaluation trial. The study was to progress to a full-scale trial if pre-defined
80 recruitment targets were met (12). In this paper, we report on the findings of the internal pilot.

81

82 **Methods**

83

84 **Study Design**

85 This study is a multi-centre, parallel group, randomised controlled trial (RCT) designed to evaluate
86 the clinical effectiveness and cost-effectiveness of ICCS for young people experiencing

87 psychiatric emergencies. The trial incorporated an internal pilot phase to assess the feasibility of
88 recruitment before determining whether to proceed to a full-scale trial. The study compares ICCS
89 with treatment as usual (TAU) across NHS Trusts in England. This pilot study is reported in
90 accordance with the CONSORT 2010 extension for pilot and feasibility trials—a reporting
91 framework rather than a methodological design guide—to ensure transparent presentation of
92 feasibility objectives, process outcomes, and pilot-specific considerations. Ethics approval was
93 obtained prior to commencement.

94 95 **Participant Selection**

96 Inclusion criteria required that participants be young people aged 12 to 17 years assessed by a
97 consultant psychiatrist—typically within CAMHS crisis teams, paediatric wards, or emergency
98 departments—as meeting clinical criteria for inpatient psychiatric admission or ICCS in
99 participating NHS Trusts. To qualify for inpatient admission, at least one of the following had to
100 be present: (1) acute suicidality requiring 24-hour observation; (2) recent medically significant
101 suicide attempt; (3) new-onset or exacerbated psychosis; (4) severe affective dysregulation
102 unmanageable in the community. Clinical eligibility for ICCS was determined by a consultant
103 psychiatrist or senior ICCS clinician using all of the following criteria: (1) clinical stability suitable
104 for intensive community care (i.e., absence of active psychosis or severe affective dysregulation
105 requiring inpatient supervision); (2) Children’s Global Assessment Scale (CGAS) score ≥ 20 ; (3)
106 no acute risk necessitating 24-hour observation. Participants needed to demonstrate the ability to
107 provide informed consent (or assent with parental consent for participants under 16 years).
108 Exclusion criteria included individuals unable to consent due to mental state, those at a risk level
109 incompatible with community care (CGAS score <20), and participants who could not be enrolled
110 because local ICCS or TAU teams had reached full capacity (12).

111 112 **Randomisation and Blinding**

113 Participants were randomised in a 1:1 ratio to ICCS or TAU using a web-based randomisation
114 system managed by King’s Clinical Trials Unit (KCTU). Randomisation was stratified by NHS
115 Trust using variable block sizes. Outcome assessors were blinded to group allocation, while
116 participants and clinicians were aware of treatment assignments. The senior trial statistician and
117 senior trial health economist remained blinded until the final stages of analysis, and full unblinding
118 of the junior trial statistician and trial health economist occurred only after the final database
119 extract in June 2024.

120 121 **Interventions**

122 The ICCS pathway is a specialised care model designed to treat young people with severe
123 psychiatric disturbances within community settings rather than hospitals. This approach is
124 implemented by multidisciplinary teams consisting of psychiatrists, psychologists, social workers,
125 and nurses, offering a tailored, evidence-based treatment plan for each service user. The core of
126 ICCS involves maintaining a low service user-to-provider ratio, typically no more than 10:1,
127 ensuring personalised and intensive care. Teams meet regularly to coordinate and evaluate
128 individual care plans, ensuring a collaborative and adaptive treatment approach. Interactions with
129 service users occur mainly in community settings such as homes, schools, and cultural centres,
130 facilitating access to natural support networks and enhancing engagement. These interactions
131 are frequent, with multiple weekly contacts to maintain engagement and monitor progress. To
132 provide comprehensive care, ICCS integrates psychological, pharmacological, and social
133 interventions, including supported discharge from inpatient care, providing an alternative to
134 inpatient admissions and outreach services. Additionally, operational standards are rigorously
135 maintained with clearly defined criteria for admission, ongoing care, and discharge, which
136 includes out-of-hours support and proactive involvement in hospital admissions. This model aims
137 to provide an effective alternative to inpatient care, focusing on immediate stabilisation and long-

138 term wellness. It supports the young person's reintegration into their community and everyday
 139 activities, such as education and employment. The ICCS pathway was based on the
 140 characteristics defined by a consensus meeting of the investigators (13). The TAU pathway
 141 includes the standard inpatient and outpatient services available within the CAMHS framework,
 142 excluding the ICCS. TAU for those young people considered for inpatient care typically includes
 143 hospital admissions but can vary widely depending on the specific protocols and resources of the
 144 participating NHS organisations. TAU typically begins with an assessment of the young person's
 145 mental health needs, followed by a corresponding treatment plan that could involve a combination
 146 of psychological, pharmacological, and social interventions. Inpatient care, when utilised under
 147 TAU, involves hospitalisation, aiming to stabilise the patient through intensive support and
 148 monitoring. The duration of hospital treatment varies, but it is followed by standard community
 149 treatment, which includes regular follow-up visits to outpatient services to ensure ongoing support
 150 and care continuity. Outpatient treatment under TAU may involve regular therapy sessions,
 151 medication management, and other supportive services like education about mental health,
 152 coping strategies, and relapse prevention. These services are designed to manage symptoms
 153 and support the young person's mental health without the intensive community integration focus
 154 seen in ICCS. The control arm's approach is a comparative standard to evaluate the effectiveness
 155 and efficiency of the more intensive, community-focused ICCS model. This comparison aims to
 156 delineate the benefits of implementing a more proactive and integrated treatment approach within
 157 the community setting instead of conventional psychiatric treatment modalities. Key intervention
 158 components are summarised in **Table 1** (TIDieR checklist).
 159

160

Table 1: TIDieR summary of ICCS versus TAU intervention components

TIDieR Item	ICCS	TAU
Why	Provide intensive, community-based crisis support to reduce time to EET and avoid admission	Deliver standard CAMHS care, including outpatient and inpatient treatment as clinically indicated
What	Multidisciplinary home-based crisis service with daily in-person or telehealth contacts; optional day-hospital sessions	Standard CAMHS input (psychological/ pharmacological) delivered in outpatient clinics and inpatient settings as required
Who	Consultant psychiatrist, psychologist, community psychiatric nurse, social worker	CAMHS psychiatrist or community psychiatric nurse
How & where	Flexible outreach—home visits or remote contacts; patient's home or day-hospital facilities	Office-based clinic appointments at CAMHS outpatient clinics
When & how much	Daily contacts until clinical goals met (target within ~3 months)	Weekly or fortnightly appointments per local policy
Fidelity & Contamination	Fidelity tools piloted at 2 sites but not consistently collected; contamination not systematically assessed	Not monitored

161

162 **Trial feasibility assessment**

163 The feasibility of proceeding to a full evaluation trial was assessed at the end of the internal pilot
 164 phase. The following criterion had been pre-specified: recruitment of at least 55 participants within
 165 the first 12 months. Recruitment of ≥ 55 participants in 12 months was the sole progression
 166 criterion; fidelity monitoring and data completeness were tracked for internal oversight but were
 167 not prespecified as progression criteria.

168 Process variables

169 We collected the number of contacts with mental health professionals and treatment exposure.
170 These data were extracted from participants' medical records. Adherence to intervention was
171 assessed by comparing the number of treatment sessions offered with the number of treatment
172 sessions attended.

173

174 Primary and Secondary Outcomes

175 The evaluation trial's primary outcome was the time to return to or start EET, measured from
176 randomisation to the first day attending EET. Participants not returning to EET by the six-month
177 follow-up were censored at their last contact date. Any return to or start of EET—regardless of
178 duration—was counted from the date of first attendance, with engagement dates verified through
179 clinical records and confirmation from educational or employment providers. Ambiguous cases
180 (e.g., minimal attendance or short-term employment) were reviewed at weekly trial meetings and
181 adjudicated on a case-by-case basis. Adjudicators were blind to treatment allocation. This
182 outcome reflects the integration of young people back into their normal activities, which is a critical
183 indicator of recovery and social functioning. It was assessed through reports from clinical teams
184 and educational or employment institutions to verify the young person's engagement with EET,
185 capturing the effectiveness of the intervention in facilitating a quicker return to daily life and
186 productivity (10).

187

188 The secondary outcomes encompassed a broad range of measures designed to evaluate the
189 impact of the interventions on young people's clinical symptoms, functioning, satisfaction with
190 services, and overall mental health. The outcomes include assessments of mental health status
191 using the Child version of the Strengths and Difficulties Questionnaire (SDQ; self-report) and the
192 Children's Global Assessment Scale (CGAS; clinician-rated). These instruments were
193 administered at baseline and at 6 months post-randomisation to measure emotional and
194 behavioral problems and overall mental functioning. Clinical severity was captured through the
195 Clinical Global Impressions (CGI) and CGI Improvement Scales (clinician-rated). These provide
196 clinician-reported evaluations of the patient's global functioning at baseline and changes post-
197 intervention at 6 months. Patient satisfaction was gauged using the ChASE (child self-report)
198 questionnaire, scheduled for 6 months after randomisation. General health and social functioning
199 were tracked using Section A of the Health of the Nation Outcome Scales for Children and
200 Adolescents (HoNOSCA; clinician-rated) at the beginning and end of the study period. Self-harm
201 thoughts and behaviours were assessed with the Self-Harm Questionnaire (self-report),
202 administered at baseline and study end. Finally, the length of hospital stay was quantified by the
203 number of nights spent in psychiatric inpatient services, extracted from electronic patient records
204 (record-based) over the 6-month follow-up.

205

206 Data collection and retention

207 To maximise follow-up, we employed flexible contact strategies—including telephone interviews,
208 text reminders, and home or clinic visits—and enlisted treating clinicians to facilitate participant
209 engagement with assessments.

210

211 Health Economic Measures

212 Service use was measured in interviews using a modified Child and Adolescent Service Use
213 Schedule (CA-SUS; (14)). A brief version of the CA-SUS was used at baseline, covering key
214 service use over the previous three months as it was hypothesized that it would be difficult for
215 participants to complete a detailed measure upon admission to a hospital experiencing a mental
216 health crisis. Key services were high cost and/or high usage (hospital inpatient, outpatient, A&E
217 and ambulance services, GPs, practice nurses, CAMHS workers, and therapists providing talking
218 therapy). A detailed CA-SUS was used at 6-month follow-up covering all health and social care

219 service use since baseline, excluding CAMHS contacts and psychiatric inpatient and day patient
220 use, which were collected directly from medical records to maximise the accuracy of intervention
221 data and minimise unblinding research assessors to group allocation.
222

223 The economic outcome measure was quality adjusted life years (QALYs) derived from the Child
224 Health Utility (CHU9D) measure of health-related quality of life at baseline and 6-months post-
225 randomisation. The CHU9D is a paediatric generic preference-based measure of health-related
226 quality of life, consisting of nine dimensions (sad, worried, pain, annoyed, tired, homework or
227 schoolwork, daily routine, activities, and sleep) rated using five levels (15). It is a valid and
228 responsive utility measure for use in young people (16) (17).
229

230 **Adverse Events (AE)**

231 Clinical teams monitored safety throughout the study. Any unfavourable or unintended signs,
232 symptoms, or illnesses (AE) were recorded, including exacerbations of pre-existing illnesses,
233 increased frequency or intensity of pre-existing episodic events or conditions, conditions detected
234 after randomisation, and continuous persistent disease or symptoms present at baseline that
235 worsen following randomisation. AEs were reported from the signing of the study consent form to
236 the last follow-up assessment 6 months after randomisation.
237

238 **Sample size for the evaluation trial**

239 The target sample size if the study proceeded to a full evaluation trial was initially 252 young
240 people (126 per group). A 20% reduction in the proportion of young people not in EET (NEET)
241 was chosen as the minimum clinically significant difference (TAU: 49% NEET, ICCS: 29% NEET).
242 Assuming 90% power and 5% significance using a two-tailed log rank test required a sample size
243 of 240 young people, adjusting for 5% loss to follow-up required a final sample size of 252 young
244 people (126 per arm). Recruitment for the evaluation trial was planned over 42 months (3.5 years),
245 equating to approximately 72 participants per year. For the internal pilot, progression criteria were
246 based solely on the number of participants recruited in the first 12 months, using a traffic-light
247 framework. In this framework, <41 participants was red (stop), 41–54 was amber (review/amend),
248 and 55–69 was green (continue). Thus, ≥ 55 recruits in 12 months ($\approx 80\%$ of the annualised target
249 of 72) was adopted as the progression criterion, representing a pragmatic feasibility threshold
250 consistent with the overall sample size calculation while accommodating site ramp-up and service
251 variation.
252

253 **Data Analysis**

254 After the study stopped recruiting at the end of the pilot phase (see Results), the statistical
255 analysis plan was adapted to estimate ICCS effect sizes based on the pilot sample. Thus, the
256 objective of the statistical analyses became the provision of effect size estimates that can inform
257 future evaluation studies. The objective is not to formally evaluate the benefit of ICCS. The latter
258 is not possible due to a lack of power, and we deliberately do not report any p-values. All analyses
259 were conducted using the intention-to-treat (ITT) principle. The primary analysis compared time
260 to EET between ICCS and TAU using Cox proportional hazards models, adjusting for NHS Trust
261 (SLaM, Berkshire, or Other). Kaplan-Meier survival curves were generated, and proportional
262 hazards assumptions were assessed using Schoenfeld residuals. Secondary outcomes were
263 analysed using linear or logistic regression models, adjusted for NHS Trust and for baseline
264 values where appropriate. For time-to-event analyses, participants without an event were
265 censored at the date of last contact. Secondary continuous and binary outcomes were analysed
266 using complete case analysis. Missing baseline covariates were managed using the missing
267 indicator method for continuous variables. No multiple imputation was performed, given the small
268 sample size. The analysis population included all randomised participants who provided baseline

269 data. Bootstrapped confidence intervals were generated for continuous outcomes with skewed
270 model residuals.

271

272 **Economic analysis**

273 The economic evaluation was based on the NHS/Personal Social Services perspective preferred
274 by NICE (18), including education-based health and social care services. Unit costs in Great
275 British pounds for the financial year 2021-2022 were applied to individual-level service use data
276 to calculate total costs per participant (supplementary **Table S1** and **S2**). All costs occurred within
277 a 6-month timeframe, and discounting was therefore not applicable. QALYs were calculated using
278 the recommended area under the curve approach (19) and applying appropriate utility weights
279 (20). The low numbers recruited to the trial negated the feasibility of conducting an economic
280 evaluation. We instead summarised and descriptively presented the following: (i) service use by
281 group over the follow-up period, reporting the mean (SD) and percentage of the sample using
282 each item; (ii) cost of service use by group over the follow-up period, reporting the mean (SD);
283 (iii) CHU9D score and QALYs by group, reporting the mean (SD).

284

285 **Results**

286

287 **Participant Recruitment and Trial Feasibility Assessment**

288 Figure 1 illustrates the flow of participants throughout the study. At least 977 young people were
289 screened for eligibility across multiple NHS Trusts, with 36 participants (3.7%) eventually
290 randomised between **23/02/22** and 01/08/23. All 15 participants randomised to ICCS were
291 included in the primary survival analysis. For the TAU group, 20 out of 21 participants contributed
292 to this analysis. Among the four participants who withdrew from the TAU group, only one did not
293 provide any data for either primary or secondary analyses. The feasibility of a full evaluation trial
294 was assessed at the end of the pilot phase (August 2023). By that time, a total of 36 participants
295 were recruited, short of the target of 55. Recruitment difficulties were most often due to safety
296 risks, which eliminated 206 potential participants, but also reflected capacity and suitability
297 constraints (e.g. ICCS at capacity, unsuitable for randomisation). Thus, the progression criteria
298 for the internal pilot phase were not met, and the study did not progress to the full RCT. This
299 small size of the pilot sample limits the power of any group comparisons for ICCS effectiveness
300 and cost effectiveness evaluation and thus, the sample was only analysed for the purpose of
301 estimating the ICCS effect sizes to plan future evaluation studies. Among those screened, 897
302 young people were deemed not eligible. The most common reason ($n = 433$) was recorded as
303 “Unwilling for CAMHS,” referring to young people or families who declined engagement with
304 specialist child and adolescent mental health services—often due to prior negative experiences,
305 perceived stigma, or a preference for informal or primary care support. Other exclusion categories
306 included: “Safety risk” ($n = 206$), where clinical risk (e.g., suicidality or aggression) was deemed
307 too high for ICCS to manage safely; “Below ICCS threshold” ($n = 12$), referring to young people
308 who did not meet ICCS criteria such as a CGAS score ≥ 20 ; and “Unsuitable for randomisation”
309 ($n = 11$), where clinicians were unable to maintain equipoise or where only one service pathway
310 was practically available. No exclusions were documented due to unavailability of TAU during the
311 pilot phase.

ARTICLE IN PRESS

312

313 **Figure 1.** CONSORT diagram presents the participant flow in the IVY Trial, from screening (n≥977) through
314 to randomization into ICCS (n=15) and TAU (n=21). The diagram details numbers approached, eligible,
315 and consented, along with retention and reasons for withdrawal at the 6-month follow-up.

316

317 **Baseline characteristics of the pilot sample**

318 The clinical and demographic characteristics of the pilot sample are summarised in **Table 2**. The
319 majority of participants were female (77.8%), with a mean age of 15.8 years (SD = 1.3). Baseline

320 demographic characteristics were well balanced between the two treatment arms. The ethnic
 321 composition of the sample included 47.2% White, 25% Black/African/Caribbean/Black British, and
 322 13.9% Mixed/Multiple ethnic groups. The majority of participants (94.4%) had no prior involvement
 323 with ICCS. At baseline, 7 participants (19.4%) had a diagnosis of autism spectrum disorder (ASD),
 324 while none were diagnosed with borderline personality disorder (BPD).. At study entry, 15 of 36
 325 participants (41.7%) were already engaged in education, employment, or training (EET), while 21
 326 (58.3%) were not; detailed information on the intensity of baseline engagement (e.g., full-time vs.
 327 part-time) was not collected.
 328
 329

Table 2. Baseline demographic and clinical variables by trial arm and overall

Baseline demographic	TAU (N=21)	ICCS (N=15)	Overall (N=36)
Engaged in EET at baseline – n (%)	8 (38.1%)	7 (46.7%)	15 (41.7%)
Age at randomisation (n)			
mean (SD)	15.9 (1.2)	15.7 (1.3)	15.8 (1.3)
median (IQR)	16.4 (15.2-16.6)	16.0 (14.6-16.9)	16.1 (15.0-16.8)
Participant sex at birth - n (%)			
Male	5 (23.8%)	3 (20.0%)	8 (22.2%)
Female	16 (76.2%)	12 (80.0%)	28 (77.8%)
Ethnic group - n (%)			
White	11 (52.4%)	6 (40.0%)	17 (47.2%)
Mixed/Multiple ethnic groups	1 (4.8%)	4 (26.7%)	5 (13.9%)
Asian/Asian British	3 (14.3%)	1 (6.7%)	4 (11.1%)
Black/ African/Caribbean/Black British	6 (28.6%)	3 (20.0%)	9 (25.0%)
Other ethnic group	0 (0.0%)	1 (6.7%)	1 (2.8%)
IMD Decile - n (%)			
2 - more deprived	2 (9.5%)	2 (13.3%)	4 (11.1%)
3	4 (19.0%)	2 (13.3%)	6 (16.7%)
4	3 (14.3%)	0 (0.0%)	3 (8.3%)
5	1 (4.8%)	2 (13.3%)	3 (8.3%)
6	2 (9.5%)	1 (6.7%)	3 (8.3%)
7	1 (4.8%)	1 (6.7%)	2 (5.6%)
8	3 (14.3%)	1 (6.7%)	4 (11.1%)
9	3 (14.3%)	1 (6.7%)	4 (11.1%)
10 - least deprived	2 (9.5%)	5 (33.3%)	7 (19.4%)
Country of residence – England, n (%)	21 (100.0%)	15 (100.0%)	36 (100.0%)
Is self-reported gender same as sex at birth - n (%)			
No	2 (9.5%)	0 (0.0%)	2 (5.6%)
Yes	19 (90.5%)	15 (100.0%)	34 (94.4%)
BPD diagnosis – None, n (%)	21 (100.0%)	15 (100.0%)	36 (100.0%)
Psychosis Diagnosis - n (%)			
No	17 (81.0%)	14 (93.3%)	31 (86.1%)
Yes	4 (19.0%)	1 (6.7%)	5 (13.9%)
ASD Diagnosis - n (%)			
No	18 (85.7%)	11 (73.3%)	29 (80.6%)
Yes	3 (14.3%)	4 (26.7%)	7 (19.4%)
Previous input from ICCS - n (%)			
No	20 (95.2%)	14 (93.3%)	34 (94.4%)
Yes	1 (4.8%)	1 (6.7%)	2 (5.6%)

330 *IMD = Index of Multiple Deprivation; EET = Education, Employment or Training; NEET = Not in Education,*
 331 *Employment or Training; CAMHS = Child and Adolescent Mental Health Services; ASD = Autism Spectrum*
 332 *Disorder; BPD = Borderline Personality Disorder; SD = Standard Deviation; IQR = Interquartile Range.*
 333

334 **Data completeness**

335 Follow-up data for the primary EET outcome were available for 85% of participants, with up to
336 30% missingness on secondary outcomes.

337

338 **Treatment exposure and adherence**

339 The total number of mental health contacts and treatment exposure are summarised in **Tables**
340 **S3 and S4**. The median number of patient contacts with most types of mental health workers was
341 0, suggesting that most IVY participants did not have many mental health contacts over the
342 observation period. There was a good adherence to ICCS treatment. Young people were offered
343 a median of 14.0 (IQR 6.0-18.0) ICCS appointments, of which a median of 11.0 (IQR 6.0-16.0)
344 were attended. In addition to the ICCS treatment, young people in the ICCS arm were offered a
345 median of 5.0 (IQR 1.0-13.0) standard community treatment sessions, and they attended a
346 median of 5.0 (IQR 1.0-8.0) of these sessions. In TAU, young people were offered a median of
347 8.0 (IQR 2.5-15.0) standard community treatment sessions, of which a median of 5.5 (IQR 2.5-
348 9.5) were attended. Despite TAU permitting inpatient care, very few TAU participants experienced
349 any hospital admission during follow-up

350

351 **ICCS effect sizes in terms of trial outcomes**

352 The primary trial outcome was the time to start or return to EET. Among the 36 participants, 30
353 (83.3%) started or returned to EET within the 6-month follow-up period. The median unadjusted
354 time to EET was 9 days overall (interquartile range [IQR]: 1-49). Participants in the ICCS arm had
355 a shorter median unadjusted time to EET (6 days, IQR: 1-35) than those in the TAU arm (12 days,
356 IQR: 2-84), though the interquartile ranges overlapped. The unadjusted Kaplan-Meier survival
357 analysis (**Figure 2**) showed a faster transition to EET in the ICCS arm compared to TAU. After
358 adjusting for NHS Trust, we estimate that allocation to ICCS is associated with a higher probability
359 of returning to /starting EET in our sample (HR: 1.34, 95% CI: 0.63 - 2.86).

360

361

362

363

364

Figure 2. Kaplan-Meier curves depict survival probabilities, where "surviving" is defined as not engaging in employment, education, or training (NEET) for participants in the ICCS and TAU arms. All data are included following the intention-to-treat principle. The plot accounts for five participants who started/returned to EET on the same day they were randomized, shown as minimal event times of 0.001 days.

365 Effect size estimates for the ten secondary trial outcomes are shown in **Table 3**. This shows that
 366 all secondary outcomes in our pilot sample improved under ICCS. In the pilot sample, allocation
 367 to ICCS was associated with lower/improved SDQ scores, higher/improved CGAS ratings,
 368 lower/improved HoNOSCA Section A scores and higher/better service satisfaction scores. No
 369 clear improvements were seen between ICCS and TAU in the odds of reporting 5+ episodes of
 370 self-harm or lengthening time in EET. Nights in hospital were omitted from the analysis because
 371 there were only 4 participants who reported being admitted to a psychiatric inpatient ward. In the
 372 pilot sample, participants randomised to ICCS had lower odds of having a 1-point
 373 increase/worsening in CGI Illness Severity rating. However, it should be noted again that we were
 374 not powered to formally assess the existence of any group differences.

375
 376 **Table 3. The effect of treatment (estimated difference between ICCS and TAU) on the**
 377 **primary and secondary outcomes, using TAU as the reference group and adjusting for**
 378 **NHS Trust and baseline values where appropriate**
 379

Outcome	N in model	Estimate [95% CI]
Time to EET (HR)	35	1.34 [0.63, 2.86]
Change in SDQ-Child	31	-0.82 [-5.89, 4.24] Bootstrapped: -0.82 [-5.89, 3.86]
Change in CGAS	33	6.99 [-0.88, 14.87]
Change in HoNOSCA Section A	30	-2.50 [-6.59, 1.58] Bootstrapped: -2.50 [-6.32, 1.36]
CGI Severity (OR)	30	0.10 [0.01, 0.69]
Multiple self-harm (OR)	31	1.03 [0.21, 5.21]
CGI Improvement (OR)	29	0.26 [0.06, 1.16]
Change in Service satisfaction (ChASE)	30	5.39 [-4.13, 14.9]
Days in EET (IRR)	29	1.21 [0.75, 1.94]
Nights in hospital (IRR)	N/A*	N/A*

*Omitted from results, only 4 participants reported being admitted to psychiatric inpatient ward.

380
 381 Abbreviations: Confidence Interval (CI), Hazard Ratio (HR), Employment/Education/Training (EET), Odds
 382 Ratio (OR), Incidence Rate Ratio (IRR), Strengths & Difficulties Questionnaire (SDQ), Children's Clinical
 383 Global Scale (CGAS), Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA),
 384 Clinical Global Impressions (CGI), Children's Assessment of Satisfaction with Services (ChASE).

385
 386
 387
 388

389 **Safety and Adverse Events**

390 A total of 12 safety events, 5 in ICCS and 7 in TAU were reported during the study period, including
391 three serious adverse events (SAEs) in the TAU and three in ICCS. All six SAEs were of mild or
392 moderate severity, and only one SAE was reported as probably related to the study intervention.

393
394 **Health economics**

395 Full economic data (full-service use and CHU9D data at baseline and 6-month follow-up) were
396 available for 28 participants (78% of all recruited participants). An equal number of participants
397 with full economic data was available in each group (n=14 ICCS; n=14 TAU). Extensive utilization
398 of hospital services for mental health reasons was observed across both study groups before the
399 trial's commencement, as shown in supplementary **Table S5**. Notably, 79% of participants in both
400 groups utilised inpatient admissions and emergency services, while outpatient appointments were
401 accessed by 32%. Engagement with CAMHS workers was also substantial, reported by 71% of
402 all participants, indicating a critical need for mental health support in this population.

403
404 Follow-up data are reported in **Tables S6 and S7** (use of intervention services and use of all other
405 health and social care services, respectively). In terms of intervention use (**Table S6**), as would
406 be expected, the ICCS group used more ICCS-specific interventions, whilst the control group
407 used more of many, although not all, of the non-ICCS-specific services. Direct comparison of
408 individual services is not meaningful, given randomisation to ICCS or TAU, but in aggregate,
409 contacts excluding inpatient admissions were higher in the ICCS group (mean 24.21, SD 18.99)
410 compared to TAU (mean 9.57, SD 10.06), whilst psychiatric inpatient nights were lower in the
411 ICCS group (mean 3.21, SD 12.03) compared to TAU (mean 15.07, SD 38.42). The use of all
412 services was low with no obvious patterns of differences between groups.

413
414 The costs of all services used between baseline and follow-up are reported in Table 4. During the
415 6-month follow-up period, the total costs related to intervention/control service use were
416 substantially lower for the ICCS group (mean £5,640, SD 10,074) compared with TAU (mean
417 £13,526, SD 31,702). Hospital and community service costs recorded in the CA-SUS were
418 broadly similar between groups (mean £1,423 vs £1,629). This resulted in lower overall 6-month
419 follow-up costs for ICCS (mean £7,063, SD 10,605) compared with TAU (£15,155, SD 31,560).
420 The wide variation in TAU costs was largely attributable to a small number of high-cost cases.
421 The calculation of QALYs based on the CHU9D utility scores from baseline to 6-month follow-up
422 revealed no significant differences in health-related quality of life between the groups (**Table 5**).

423

424

425

426

427

428

429 **Table 4. Mean Costs (£) Per Participant Over the 6 Month Follow-up**

Service	All (n=28)		ICCS (n=14)		TAU (n=14)	
	Mean £ (SD)	Range £	Mean £ (SD)	Range £	Mean £ (SD)	Range £
Hospital						
PH Inpatient	95 (369)	0-1,771	190 (513)	0-1,771	0 (0)	n/a
PH Day Case	110 (584)	0-3,088	221 (825)	0-3,088	0 (0)	n/a
PH Outpatient	292 (756)	0-3,160	301 (838)	0-3,160	282 (696)	0-2,633
A&E Attendance	77 (132)	0-432	82 (135)	0-432	72 (135)	0-432
Ambulance Services	25 (131)	0-695	0 (0)	n/a	50 (186)	0-695
Health-based Place of safety	44 (234)	0-1,236	0 (0)	n/a	88 (330)	0-1,236
Total Hospital	643 (1,742)	0-8,451	794 (2,227)	0-8,451	492 (1,139)	0-4,157
Community						
GP	71 (80)	0-369	59 (66)	0-231	82 (93)	0-369
Practice nurse	3 (7)	0-23	3 (5)	0-12	4 (9)	0-23
Other nurse	21 (80)	0-397	12 (44)	0-165	30 (106)	0-397
Therapist Talking therapy	583 (944)	0-3,960	377 (615)	0-1,650	790 (1,176)	0-3,960
Education MH Practitioner	85 (225)	0-986	88 (189)	0-657	82 (263)	0-986
Community Paediatrician	50 (184)	0-700	50 (187)	0-700	50 (187)	0-700
SEN Coordinator	5 (20)	0-75	5 (20)	0-75	5 (20)	0-75
Social worker	44 (126)	0-614	30 (78)	0-236	57 (163)	0-614
OT	12 (46)	0-210	0 (0)	n/a	24 (63)	0-210
SLT	2 (8)	0-42	3 (11)	0-42	0 (0)	n/a
Drug/alcohol Support worker	6 (30)	0-160	0 (0)	n/a	11 (43)	0-160
Helpline/advice Service	1 (3)	0-12	2 (4)	0-12	1 (2)	0-8
Total Community	883 (1,001)	0-4,727	629 (660)	0-1,742	1,137 (1,227)	104-4,727
Total						
6-month CA-SUS cost	1,526 (2,337)	140-10,061	1,423 (2,553)	144-10,061	1,629 (2,191)	141-8,884
ICCS/TAU Cost	9,583 (23,428)	0-96,391	5,640 (10,074)	217-36,432	13,526 (31,702)	0-96,391
6-month Follow-up cost	11,109 (23,467)	248-98,277	7,063 (10,605)	454-38,318	15,155 (31,560)	248-98,277

MH Mental Health; PH Physical Health; A&E Accident and Emergency; GP General Practitioner; SEN Special Education Needs; OT Occupational Therapist; SLT Speech and Language Therapist; CA-SUS Child and Adolescent Service Use Schedule.

431 **Table 5. Mean utility scores and 6-month QALYs per participant**

CHU9D	All (n=28)		ICCS (n=14)		TAU (n=14)	
	Mean (SD)	Range	Mean (SD)	Range	Mean (SD)	Range
Baseline utility	0.718 (0.151)	0.415-1.000	0.709 (0.141)	0.415-0.963	0.727 (0.166)	0.532-1.000
6-month utility	0.740 (0.127)	0.445-1.000	0.740 (0.118)	0.445-0.926	0.740 (0.139)	0.507-1.000
6-month QALYs	0.364 (0.058)	0.267-0.488	0.362 (0.055)	0.267-0.456	0.367 (0.064)	0.290-0.488

432 *CHU9D Child Health Utility-9 Dimensions; QALY Quality-Adjusted Life Year.*433 **Discussion**434 **Main Findings**

435 This study represents the first attempt at a trial conducted in the UK to evaluate the effectiveness
 436 of ICCS compared to TAU for young people with severe psychiatric disorders considered for
 437 inpatient admissions. The study did not achieve the progression criteria of the internal pilot phase,
 438 and it was concluded that conducting an evaluation trial in the UK was not feasible at this stage,
 439 the main difficulty being being safety risks that precluded randomisation for many young people,,
 440 together with capacity constraints that prevented services from offering two alternative treatment
 441 pathways at the same time, an issue that was made worse by increased demand for mental health
 442 support for young people after the COVID period.

443
 444 To aid future evaluation studies, we estimate the effect of ICCS compared to TAU in terms of
 445 planned trial outcomes. While underpowered for any formal evaluation, the results from the pilot
 446 sample are promising and support further investigation of ICCS benefits. Participants in the ICCS
 447 arm demonstrated a quicker return to EET, with a median unadjusted time to EET of 6 days,
 448 compared to 12 days in the TAU arm. This may indicate that ICCS effectively facilitates the
 449 reintegration of young people into educational and work environments following psychiatric
 450 emergencies. The limited data highlight the need for a larger, more robust study to formally assess
 451 the effectiveness of ICCS and to explore the mechanisms through which ICCS may expedite
 452 reintegration into societal roles for young people following psychiatric crises. There was no
 453 evidence of an increase in adverse events with ICCS.

454
 455 The development of the current ICCS model was significantly influenced by earlier findings from
 456 our research group (21), which compared the effectiveness of Supported Discharge Service,
 457 which represents one of three key aspects of ICCS, with standard inpatient care. Despite showing
 458 no significant differences in functional impairment and clinical outcomes, there were significant
 459 differences in educational outcomes and self-harm favouring ICCS. These findings underpinned
 460 the rationale for developing and refining community-based care models. Previous evidence of the
 461 effectiveness of one component of ICCS, together with effect size estimates in this study, might
 462 indicate that ICCS has more benefits than TAU. Given the pilot's limited sample size, we do not
 463 interpret observed treatment effect sizes and instead focus on key feasibility metrics—recruitment
 464 barriers, data completeness (15% missing primary outcome; 30% secondary), and fidelity
 465 monitoring challenges—which are essential for planning a definitive trial. To address these
 466 feasibility constraints, future evaluations could employ alternative designs such as
 467 stepped-wedge cluster trials to improve recruitment flexibility, cluster-randomised designs to

468 reduce contamination, or hybrid implementation—effectiveness trials to assess both ICCS delivery
469 and clinical outcomes concurrently (22, 23).

470
471 While ICCS is already implemented across the NHS, the substantial ineligibility rate of 91.8%
472 observed in our study underscores critical areas for potentially optimising these services.
473 Whereas most ineligible young people clearly needed one of the existing services, other factors
474 played an important role. They included reluctance to engage with CAMHS, complex risk profiles,
475 and logistical constraints like local ICCS team capacities and geographical limitations, pointing to
476 potential barriers that may restrict access to care for adolescents with psychiatric emergencies.
477 Acknowledging these barriers not only highlights the need for continuous improvement in the
478 delivery of community-based care but also calls for a deeper investigation into how these services
479 can be made more inclusive and responsive to the needs of all patients.

480
481 In this small pilot sample, the ICCS group demonstrated similar QALYs to the TAU group
482 alongside lower overall health and social care costs over the study period. These differences were
483 primarily due to higher costs of TAU service provision, while hospital and community service costs
484 were broadly similar across arms. The wide variation in TAU costs appeared to be driven by a
485 small number of high-cost cases, highlighting the sensitivity of economic findings in small samples
486 to outliers. Despite this cost difference in favour of ICCS, inferences about costs and cost-
487 effectiveness cannot be made, and no adjustments were made for baseline differences. The
488 presented data should therefore be treated cautiously and used only to generate hypotheses for
489 future research.

490
491 **ICCS Implementation in this study**
492 The implementation of ICCS in our study was conservative. We required all participating ICCS to
493 have access to a day hospital service, which excluded a significant number of services. This
494 conservative approach ensured a consistent standard of care across all ICCS settings in the
495 study. It may have limited the generalisability of our findings to other ICCS models that do not
496 incorporate day hospital care. This decision was made to strengthen the comparability of ICCS to
497 more structured services like inpatient care, but it restricted the diversity of ICCS approaches that
498 could be explored in this trial.

499
500 **Engagement with Treatment**
501 Unlike many other studies of psychiatric treatments, where engagement is often suboptimal, we
502 observed good engagement to both ICCS and TAU. This was particularly notable given the severe
503 psychiatric disorders in our sample. The active engagement of young people and their families in
504 treatment may reflect the high level of need and the tailored, intensive nature of ICCS. However,
505 it should also be noted that engagement may have been facilitated by the strong relationships
506 between clinical teams and participants, which could be less pronounced in larger, more diverse
507 trials.

508
509 **Real-Life Study Design**
510 Our study was conducted in real-life clinical services, which adds to the ecological validity of the
511 findings. However, this also presented several challenges, notably the impact of the COVID-19
512 pandemic, which affected service delivery and recruitment. The pandemic led to increased
513 demand for mental health services, which may have influenced the capacity of clinical teams to
514 refer young people to the trial and impacted their decision-making regarding the most appropriate
515 care pathway for each individual. Despite these challenges, our study maintained a high follow-
516 up rate for the primary outcome measure, which strengthened the reliability of the data we were
517 able to collect.

518

519 Recruitment was one of the main challenges of this trial, with several obstacles uncovered during
520 the feasibility phase. One significant barrier was the determination of clinical teams about which
521 pathway (ICCS or TAU) was most suitable for individual young people, given the risk profile. In
522 many cases, only one pathway was available and teams based their decisions on limited evidence
523 and clinical experience rather than randomisation, which led to slower recruitment rates.
524 Additionally, the high level of complexity and acuity of the participants' conditions may have
525 influenced clinicians' willingness to randomise them into different care pathways, reflecting real-
526 world concerns about service suitability.

527

528 **Limitations**

529 The most significant limitation of this pilot study is the very small sample size, which was a direct
530 result of recruitment difficulties. As a result, we were unable to draw any inferences about the
531 effectiveness or cost-effectiveness of ICCS relative to TAU. Additionally, it was not possible to
532 blind participants to the intervention they were receiving, which may have introduced bias in self-
533 reported outcomes such as satisfaction and functioning. We also acknowledge that specific
534 reasons for referral to ICCS or inpatient admission were not systematically recorded, limiting our
535 ability to characterise the full clinical context for eligibility decisions. Future trials should
536 incorporate structured collection of referral indications across sites. While fidelity monitoring tools
537 were piloted at two sites, we did not achieve consistent fidelity data collection across all sites nor
538 formally assess potential contamination between study arms; future work should incorporate
539 these measures to bolster internal validity. The low number of TAU hospitalisations—which may
540 reflect bed shortages, clinician reluctance to admit, or early symptom resolution—limits our ability
541 to assess ICCS's hospital-avoidance function in this pilot. A further important limitation is that the
542 primary outcome of time to EET was only applicable to the 58.3% of participants who were NEET
543 at baseline (n = 21). This constrains the interpretation of our clinical findings and highlights the
544 need for future trials to consider either restricting inclusion to NEET participants or adopting a
545 continuous measure of functioning (e.g., CGAS) as both an eligibility criterion and outcome. We
546 also note that 41.7% of participants were already engaged in education, employment, or training
547 at baseline; without data on the intensity of that engagement (e.g., full- vs. part-time), our time-to-
548 EET outcome may be influenced by pre-existing participation, and future studies should record
549 both the presence and extent of baseline EET involvement. We observed 15% missing data for
550 the primary EET outcome and up to 30% missingness on secondary measures. Although
551 mitigated by flexible contact and clinician support, future trials should employ digital data-capture
552 platforms and automated reminders to further improve retention and minimise missing data.

553

554 **Strengths**

555 Despite the limitations, this study has several strengths. It is the first randomised study in the UK
556 to directly compare ICCS with existing services for young people with severe psychiatric
557 disorders, providing important preliminary data in an area with limited research. Our sample was
558 diverse, both in terms of demographics and psychiatric diagnoses, and the real-world clinical
559 setting enhances the generalizability of the findings to everyday practice. Moreover, the study
560 demonstrated high adherence rates and good participant engagement, which is promising for
561 future trials involving this population.

562

563 **Implications**

564 In conclusion, this pilot RCT suggests that ICCS may be a promising intervention for young people
565 with severe psychiatric disorders. Although the sample size was insufficient to draw definitive
566 conclusions, the effect size estimates are promising and previous studies indicate that one aspect
567 of ICCS, Supported Discharge Service, appears to be efficacious in terms of school reintegration
568 and reducing self-harm. Future studies with larger sample sizes are necessary to confirm the
569 findings of this study and explore the full potential of ICCS as an alternative to inpatient and other

570 community-based services for young people with severe mental health needs. An ongoing post-
 571 implementation evaluation should be done for those areas that implement ICCS possibly utilising
 572 routinely collected outcome data. This study also provides important information to support such
 573 future research, including insights into recruitment challenges and data completeness. While
 574 exploratory effect size estimates were reported, these are imprecise given the small sample size
 575 and should not be used directly for powering future trials. Instead, formal sample size calculations
 576 should follow best practice guidance such as the DELTA-2 framework (24).
 577

578 **Supplementary Materials**

579 Supplementary material is available online at
 580

581 **List of abbreviations**

582
 583 A&E: Accident and Emergency
 584 AE: Adverse Event
 585 ASD: Autism Spectrum Disorder
 586 BPD: Borderline Personality Disorder
 587 CA-SUS: Child and Adolescent Service Use Schedule
 588 CAMHS: Child and Adolescent Mental Health Services
 589 CBCL: Child Behavior Checklist
 590 CGAS: Children's Global Assessment Scale
 591 CGI: Clinical Global Impressions
 592 ChASE: Children's Assessment of Satisfaction with Services
 593 CHU9D: Child Health Utility-9 Dimensions
 594 CI: Confidence Interval
 595 CONSORT: Consolidated Standards of Reporting Trials
 596 EET: Education, Employment or Training
 597 GP: General Practitioner
 598 HoNOSCA: Health of the Nation Outcome Scales for Children and Adolescents
 599 HR: Hazard Ratio
 600 ICCS: Intensive Community Care Services
 601 IMD: Index of Multiple Deprivation
 602 IRR: Incidence Rate Ratio
 603 IQR: Interquartile Range
 604 ITT: Intention-to-Treat
 605 NEET: Not in Education, Employment or Training
 606 NHS: National Health Service
 607 OR: Odds Ratio
 608 OT: Occupational Therapist
 609 QALY: Quality-Adjusted Life Year
 610 RA: Research Assistant
 611 RCT: Randomised Controlled Trial
 612 REC: Research Ethics Committee
 613 SAE: Serious Adverse Event
 614 SD: Standard Deviation
 615 SDQ: Strengths and Difficulties Questionnaire
 616 SEN: Special Educational Needs
 617 SLT: Speech and Language Therapist
 618 TAU: Treatment as Usual

619 **Declaration**

620

621 **Ethics approval and consent to participate**

622 Ethical approval for this study was granted by the West Midlands and Black Country Research
623 Ethics Committee (REC reference: 20/WM/0069). The trial was prospectively registered with the
624 ISRCTN registry (ISRCTN42999542; registration date: 29 April 2020). All participants, or their
625 legal guardians for those under 16 years of age, provided written informed consent prior to
626 enrolment. The study was conducted in accordance with the Declaration of Helsinki (1975), as
627 revised in 2013, and complied with all relevant national and institutional ethical standards.
628

629 **Consent for publication**

630 Not applicable

631

632 **Availability of data and materials**

633 All data generated or analysed during this study are included in this published article and its
634 supplementary materials

635

636 **Competing interests**

637 The authors declare that they have no competing interests.

638

639 **Funding**

640 This study was funded by the National Institute for Health and Care Research (NIHR) Health
641 Technology Assessment (HTA) Programme (Ref: NIHR127408). The funder had no role in the
642 design of the study, data collection, analysis, interpretation, or writing of the manuscript. SL and
643 SB were supported by the NIHR Maudsley Biomedical Research Centre at South London and
644 Maudsley NHS Foundation Trust and King's College London. SL was also supported by the NIHR
645 Applied Research Collaboration South London (NIHR ARC South London) at King's College
646 Hospital NHS Foundation Trust.

647

648 **Authors' contributions**

649 DO, SB, TZ, and SL conceived the study and obtained funding. SL and PC conducted the
650 statistical analyses. SB, MH, and ET performed the health economic evaluation. All authors
651 contributed to the interpretation of findings, critically reviewed the manuscript for intellectual
652 content, and approved the final version.

653

654 **Acknowledgements**

655 The authors would like to thank the young people and families who participated in the study during
656 an exceptionally challenging period in their lives. We are also grateful to the NHS Trusts and
657 Health Boards that supported recruitment and delivery of the study.

658

659 **Authors' information (optional)**

660 **Dennis Ougrin**, MBBS, PhD, Wolfson Institute of Population Health, Queen Mary University of
661 London, London, United Kingdom; **Thilipan Thaventhiran**, PhD, Queen Mary University of

662 London, London, United Kingdom; **Ben Hoi-Ching Wong**, MSc, East London NHS Foundation
 663 Trust, London, United Kingdom; **Izabela Pilecka**, PhD, King's College London, London, United
 664 Kingdom; **Sabine Landau**, PhD, King's College London, London, United Kingdom; **Sarah**
 665 **Byford**, PhD, King's College London, London, United Kingdom; **Petrina Chu**, MSc, King's
 666 College London, London, United Kingdom; **Hassan Jafari**, PhD, King's College London, London,
 667 United Kingdom; , **Margaret Heslin**, PhD, King's College London, London, United Kingdom;
 668 **Emma Tassie**, PhD, King's College London, London, United Kingdom; **Paula Reavey**, PhD,
 669 London South Bank University, London, United Kingdom; **Toby Zundel**, MBBS, South London
 670 and Maudsley NHS Foundation Trust, London, United Kingdom; **Mandy Wait**, South London and
 671 Maudsley NHS Foundation Trust, London, United Kingdom; **Ruth Woolhouse**, East London NHS
 672 Foundation Trust, London, United Kingdom; **Tauseef Mehdi**, MBBS, Berkshire Healthcare NHS
 673 Foundation Trust, Bracknell, United Kingdom; **Jovanka Tolmac**, MBBS, Central and North West
 674 London NHS Foundation Trust, London, United Kingdom; **Joe Clacey**, MBBS, Oxford Health
 675 NHS Foundation Trust, Oxford, United Kingdom; **Leon Wehncke**, MBChB, North East London
 676 NHS Foundation Trust, London, United Kingdom; **Veronika Beatrice Dobler**, PhD,
 677 Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom; **Rhys**
 678 **Bevan-Jones**, MBChB, PhD, Cardiff University, Cardiff, United Kingdom.

679 **Correspondence:** Thilipan Thaventhiran. Email: thilipan.thaventhiran@nhs.net. Wolfson Institute of
 680 Preventive Medicine. Queen Mary University London, Charterhouse Square, London EC1M 6BQ.

681 References

- 682
- 683 1. Newlove-Delgado TM, Williams; Mandalia, D.; Davis, J.; McManus, S.; Savic, M.; Treloar,
 684 W.; Ford, T. Mental Health of Children and Young People in England, 2022. England; 2022.
 - 685 2. Fisher D. National Estimates, August 2021 to March 2022. England; 2022.
 - 686 3. Green J, Jacobs B, Beecham J, Dunn G, Kroll L, Tobias C, et al. Inpatient treatment in child
 687 and adolescent psychiatry--a prospective study of health gain and costs. *J Child Psychol*
 688 *Psychiatry*. 2007;48(12):1259-67.
 - 689 4. Stewart SL, Semovski V, Lapshina N. Adolescent Inpatient Mental Health Admissions: An
 690 Exploration of Interpersonal Polyvictimization, Family Dysfunction, Self-Harm and Suicidal
 691 Behaviours. *Child Psychiatry Hum Dev*. 2024;55(4):963-74.
 - 692 5. Miller DAA, Ronis ST, Slaunwhite AK, Audas R, Richard J, Tilleczek K, et al. Longitudinal
 693 examination of youth readmission to mental health inpatient units. *Child Adolesc Ment Health*.
 694 2020;25(4):238-48.
 - 695 6. Care) DDoHaS. Reforming the Mental Health Act: Government response to consultation.
 696 London, UK; 2021.
 - 697 7. Ougrin D, Zundel T, Corrigall R, Padmore J, Loh C. Innovations in Practice: pilot evaluation
 698 of the supported discharge service (SDS): clinical outcomes and service use. *Child Adolesc*
 699 *Ment Health*. 2014;19(4):265-9.
 - 700 8. Clisu DA, Layther I, Dover D, Viner RM, Read T, Cheesman D, et al. Alternatives to mental
 701 health admissions for children and adolescents experiencing mental health crises: A
 702 systematic review of the literature. *Clin Child Psychol Psychiatry*. 2022;27(1):35-60.
 - 703 9. Ougrin D, Corrigall R, Poole J, Zundel T, Sarhane M, Slater V, et al. Comparison of
 704 effectiveness and cost-effectiveness of an intensive community supported discharge service
 705 versus treatment as usual for adolescents with psychiatric emergencies: a randomised
 706 controlled trial. *Lancet Psychiatry*. 2018;5(6):477-85.

- 707 10. Hale DR, Bevilacqua L, Viner RM. Adolescent Health and Adult Education and Employment:
708 A Systematic Review. *Pediatrics*. 2015;136(1):128-40.
- 709 11. Boege I, Corpus N, Weichard M, Schepker R, Young P, Fegert JM. Long-term outcome of
710 intensive home treatment for children and adolescents with mental health problems - 4 years
711 after a randomized controlled clinical trial. *Child Adolesc Ment Health*. 2021;26(4):310-9.
- 712 12. Thaventhiran T, Wong BH, Pilecka I, Masood S, Atanda O, Clacey J, et al. Evaluation of
713 intensive community care services for young people with psychiatric emergencies: study
714 protocol for a multi-centre parallel-group, single-blinded randomized controlled trial with an
715 internal pilot phase. *Trials*. 2024;25(1):141.
- 716 13. Keiller E, Masood S, Wong BH, Avent C, Bediako K, Bird RM, et al. Intensive community care
717 services for children and young people in psychiatric crisis: an expert opinion. *BMC Med*.
718 2023;21(1):303.
- 719 14. Byford S, Harrington R, Torgerson D, Kerfoot M, Dyer E, Harrington V, et al. Cost-
720 effectiveness analysis of a home-based social work intervention for children and adolescents
721 who have deliberately poisoned themselves. Results of a randomised controlled trial. *Br J*
722 *Psychiatry*. 1999;174:56-62.
- 723 15. Stevens K. Developing a descriptive system for a new preference-based measure of health-
724 related quality of life for children. *Qual Life Res*. 2009;18(8):1105-13.
- 725 16. Canaway AG, Frew EJ. Measuring preference-based quality of life in children aged 6-7 years:
726 a comparison of the performance of the CHU-9D and EQ-5D-Y--the WAVES pilot study. *Qual*
727 *Life Res*. 2013;22(1):173-83.
- 728 17. Furber G, Segal L. The validity of the Child Health Utility instrument (CHU9D) as a routine
729 outcome measure for use in child and adolescent mental health services. *Health Qual Life*
730 *Outcomes*. 2015;13:22.
- 731 18. Excellence NifHaC. Guide to the Methods of Technology Appraisal 2013. NICE Process and
732 Methods Guides. London2013.
- 733 19. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness
734 analysis: the importance of controlling for baseline utility. *Health Econ*. 2005;14(5):487-96.
- 735 20. Stevens K. Valuation of the Child Health Utility 9D Index. *Pharmacoeconomics*.
736 2012;30(8):729-47.
- 737 21. Ougrin D, Corrigan R, Stahl D, Poole J, Zundel T, Wait M, et al. Supported discharge service
738 versus inpatient care - evaluation (SITE): a randomised controlled trial comparing
739 effectiveness of an intensive community care service versus inpatient treatment as usual for
740 adolescents with severe psychiatric disorders: self-harm, functional impairment, and
741 educational and clinical outcomes. *Eur Child Adolesc Psychiatry*. 2021;30(9):1427-36.
- 742 22. Thabane M, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane T, Giangregorio
743 L, Goldsmith CH. A tutorial on pilot studies: the what, why and how. *BMC Med Res Methodol*.
744 2010;10(1):1.
- 745 23. Sim J, Lewis M. Feasibility and pilot study design: overcoming common pitfalls. *Pilot Feasibility*
746 *Stud*. 2019;5(1):96.
- 747 24. Cook JA, Julious SA, Sones W, Hampson LV, Hewitt CE, Berlin JA, et al. DELTA2 guidance
748 on choosing the target difference and undertaking and reporting sample size calculations for
749 randomised controlled trials. *BMJ*. 2018;363:k3750.